Innate Pharma (NASDAQ:IPHA) Shares Up 3.6% – Should You Buy?

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA)’s share price traded up 3.6% during mid-day trading on Tuesday . The company traded as high as $1.7650 and last traded at $1.72. 9,959 shares traded hands during trading, a decline of 53% from the average session volume of 21,379 shares. The stock had previously closed at $1.66.

Wall Street Analyst Weigh In

IPHA has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Innate Pharma in a research report on Thursday, January 22nd. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of Innate Pharma in a report on Wednesday, October 29th. Finally, HC Wainwright set a $5.00 target price on Innate Pharma and gave the company a “buy” rating in a research report on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Innate Pharma Price Performance

The stock’s 50 day moving average price is $1.75 and its 200-day moving average price is $1.91.

Institutional Investors Weigh In On Innate Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of IPHA. Millennium Management LLC bought a new position in shares of Innate Pharma in the fourth quarter worth about $36,000. OLD Mission Capital LLC bought a new stake in Innate Pharma during the 4th quarter valued at approximately $50,000. Finally, Jane Street Group LLC bought a new stake in Innate Pharma during the 4th quarter valued at approximately $162,000. 0.16% of the stock is owned by institutional investors.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.